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Previous studies have shown that maintaining high hemoglobin levels in patients after chemotherapy
reduced the length of neutropenia. Thus, we undertook a randomized, controlled, clinical trial in children
undergoing allogeneic bone marrow transplantation after receiving a myeloablative conditioning regimen to
compare 2 hemoglobin thresholds as triggers for red blood cell transfusion: 120 g/L in the experimental arm
and 70 g/L in the control arm. The Data and Safety Monitoring Board closed the study after enrollment of the
sixth patient because 3 patients in the experimental arm contracted veno-occlusive disease, but none in the
control arm did (P ¼ .05). Ascites was present in all 3 patients, pleura effusion in 2, and portal vein thrombosis
in 2. One patient experienced hepatic failure and required treatment with the molecular adsorbent recycling
system. Another patient required hemodialysis for renal failure. No major imbalance between groups was
seen with regard to risk factors for veno-occlusive disease. Therefore, maintaining the hemoglobin at higher
levels should be avoided after hematopoietic stem cell transplantation.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION Several clinical trials have attempted to deﬁne the best
The myeloablative preparative regimen used for hema-
topoietic stem cell transplantation (HSCT) induces profound
neutropenia. Prolonged neutropenia is associated with a
higher rate of bacterial and fungal infection and an increase
in transplantation-related mortality [1-3]. Studies conducted
before the AIDS pandemic in children with acute lympho-
blastic leukemia and in murine models have shown that
maintaining high hemoglobin levels after chemotherapy-
induced bone marrow depression accelerated granulocyte
recovery. This accelerated recovery is related to an increase
in bone marrow granulocyte progenitors, suggesting the
reduced demand for erythropoiesis leaves more stem cells
available for differentiation into nonerythroid cells [4-8].
Although granulocyte colony-stimulating factor can also be
used to accelerate neutrophil recovery, it delays platelet
engraftment as well as immune recovery and increases the
incidence of graft-versus-host disease (GVHD), treatment-
related mortality, and death [9-14]. Furthermore, other
beneﬁts of maintaining a higher level of hemoglobin after
transplantation can be expected, because higher pre-
transplantation hemoglobin levels correlate with better
survival after HSCT [15-17], and quality of life positively
correlates with hemoglobin levels in cancer patients [18].edgments on page 472.
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fusion; however, none was done in the transplantation
setting [19-22]. To date, standard practice in transplantation
patients is to transfuse RBCs according to the patient’s clin-
ical condition or systematically when hemoglobin levels fall
below 70 g/L [19]. To study the impact of using a liberal
hemoglobin threshold for RBC transfusion on granulocyte
recovery after bone marrow transplantation (BMT), we
undertook a randomized controlled trial. Children in the
experimental arm received an RBC transfusion when their
hemoglobin threshold fell below 120 g/L versus 70 g/L in the
control arm. Here, we report the results of this randomized,
controlled, clinical trial.
METHODS
Patients and Sites
This clinical trial was designed as a multicenter, randomized, controlled
study involving Canadian pediatric transplantation centers (Canadian Blood
and Marrow Transplant Group, CBMTG 0603, NCT00937053). The plan for
the study was to enroll 62 patients and randomize them to a standard
restrictive threshold (control arm) or to a liberal threshold trigger trans-
fusion strategy (experimental arm). Children aged 1 to 18 years who were
undergoing an allogeneic BMT for a malignant or benign disease (except
sickle cell disease) were eligible for enrollment. All consecutive BMT
patients were screened. Patients receiving autologous BMT, cord blood
transplantation, or peripheral stem cell transplantation were not eligible.
Patients with irregular RBC alloantibodies were also excluded. The
conditioning regimen had to be myeloablative in all cases; therefore,
either busulfan 12 mg/kg or total body irradiation 10 Gy was used. No
hematopoietic growth factor was planned before BMT, but it could be
administered posttransplantation if deemed necessary by the attending
physician. The study protocol was approved by the research ethics board at
each institution before patient enrollment, and written informed consent
was obtained from each patient or his or her legal guardian.Transplantation.
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Randomization of patients was done on the ﬁrst day of
their conditioning regimen using a web-based randomiza-
tion system. Patients in the experimental group were
transfused with RBCs to maintain a hemoglobin level
120 g/L, whereas those in the control group were trans-
fused to maintain a hemoglobin level 70 g/L. When
hemoglobin went below the threshold level, patients had to
be transfused with RBCs within 24 hours. Only previously
stored leukoreduced RBC units were used. The usual dosage
of 10 to 15 mL/kg was recommended unless the patient’s
clinical condition dictated otherwise. In case of massive
bleeding, RBC transfusions were given at the discretion of the
attending physician. This transfusion policy applied from the
ﬁrst day of the conditioning regimen to dayþ100 or until one
of the following events occurred: death, requirement for a
subsequent conditioning regimen (for a subsequent trans-
plantation), or relapse.
Strategies for platelet transfusions were also recom-
mended because it was a secondary outcome of the study.
The trigger for a platelet transfusion was 10  109/L for
patients without sepsis. The threshold was increased to
20  109/L for patients with a fever or infection. Prophylactic
platelet transfusions before invasive procedures and thera-
peutic platelet transfusions for active bleeding were given at
the discretion of the attending physician. All other inter-
ventions were done as per institutional protocol, including
graft-versus-host prophylaxis.
Baseline Assessment, Monitoring, and Outcome Measures
Patients underwent regular pretransplantation baseline
assessment, as per institutional protocol. This included,
among other tests, a complete blood count and, if appro-
priate, hemoglobin electrophoresis to rule out sickle cell
disease. Major ABO incompatibility, irregular RBC alloanti-
bodies, CD34þ and nucleated cell dose of the graft, and GVHD
prophylaxis were also documented. Data were collected by
trained research personnel on a validated case report form.
The primary outcomewas the time to neutrophil recovery
deﬁned as the time from transplantation to the ﬁrst of 3
consecutive days with a neutrophil count 0.5  109/L. We
also collected information on several secondary outcomes,
including time to platelet recovery (deﬁned as the time from
transplantation to the ﬁrst of 3 consecutive days with
a platelet count 20  109/L, without platelet transfusion in
the last 7 days), number of RBC and platelet transfusions,
hospitalization length, immune reconstitution, overall
survival, transplantation-related mortality, relapse, acute
and chronic GVHD, and chimerism. Long-term events were in
the study plan to be recorded at 1, 2, and 5 years of follow-up.
Compliance and Protocol Deviations
It was planned to do the primary analysis by intention-to-
treat. A per-protocol analysis was also planned, which
required a deﬁnition of compliance. Days with compliance
were deﬁned as (1) all days when hemoglobinwas above the
transfusion threshold level, (2) all days when there was no
measurement of hemoglobin, and (3) all days when hemo-
globin was below the transfusion threshold level and
a transfusion was given within 24 hours. Noncompliant days
were deﬁned as all days when the hemoglobin level was
below the transfusion threshold for more than 24 hours
without transfusion. Compliance was monitored up until
day þ100 or until one of the following events occurred:
death, requirement for a subsequent conditioning regimen(for a subsequent transplantation), or relapse.We considered
that compliance was achieved if more than 95% of days
fulﬁlled the deﬁnition of compliance.
Protocol deviations were also recorded. Two deviations
were deﬁned a priori as (1) RBC transfusions given although
the hemoglobin level was above the transfusion threshold
and (2) platelet transfusions given when the platelet level
was above 10  109/L. Deviations from the protocol were
accepted if the attending physician thought the patient may
have an infection or signiﬁcant bleeding. Other deviations
from the protocol were recorded on a “deviation form.”
Statistical Analysis
The study was designed as a multicenter, randomized,
clinical trial with a two-sided type I error of .05 and a type II
error of .85 to detect a 4-day difference in time to neutrophil
recovery. However, this analysis was never carried out: the
Data and Safety Monitoring Board (DSMB) closed the trial
after enrollment of the sixth patient because of the high
incidence of veno-occlusive disease (VOD) in the experi-
mental arm. The DSMB decision was based on the following:
clinical observations, statistical comparison of the data in
the 2 arms of the trial, and comparison of the data in the
experimental arm with historical control subjects. For the
latter 2 comparisons, a one-sided Fischer exact test was
used. A one-sided test was used because the hypothesis to
be tested was as follows: Is the risk of VOD in the experi-
mental group signiﬁcantly higher than that in the control
group? The experimental group was also compared with the
control group with respect to all known risk factors for VOD.
All analyses were conducted using SPSS 17 (IBM Corp.,
Armonk, NY).
RESULTS
The ﬁrst 6 patients were recruited at a single institution.
Before any other participating transplantation center had
begun to recruit patients, the study was stopped by the
DSMB for safety concerns after these initial 6 patients (4
females, 2 males) had been enrolled (3 in each arm) when all
3 patients randomized to the experimental arm were diag-
nosed with VOD (P ¼ .05 by unilateral Fischer exact test). All
patients in the control armwere transfused as planned in the
study protocol until day þ100. Conversely, all 3 patients in
the experimental arm were withdrawn from the transfusion
protocol before day þ100. A patient found the RBC trans-
fusions bothering and withdrew from the trial for this reason
on day þ10. Another patient was withdrawn at day þ25 by
the treating physician because of the occurrence of VOD as
well as 2 episodes of minor allergic reactions to the trans-
fusion. The last patient was withdrawn on dayþ8 when VOD
occurred. Five of 6 patients were alive 2 years after they
were enrolled in the trial. Patient 6 died 6 months
posttransplantation from leukemia. She underwent trans-
plantation for myelodysplastic syndrome, with 20% blasts at
the pretransplantation marrow examination.
Characteristics of patients, grafts, and outcomes are
shown in Table 1. The medical chart of every patient was
reviewed to assess whether other known or suspected VOD
risk factors could be identiﬁed [23,24]. We did not ﬁnd
differences between the two groups for most of these risk
factors. All patients received an allogeneic BMT [25], and
none had received previous abdominal radiation [25,26],
stem cell transplantation [26-28], gemtuzumab [29], or had
pre-existing liver damage [26]. All patients, 15 years old or
younger [26], underwent an allogeneic transplantation, and
Table 2
Red Blood Cell Transfusions and Hemoglobin Levels
Control Group Experimental Group
Patient no. 1 3 4 2 5 6
No. of RBC transfusions 2 1 1 3 9 14
Mean hemoglobin
level, g/L
90 94 103 130 132 118
Mean hemoglobin level
pretransfusion, g/L
69 70 69 107 111 101
Patients in the control group were transfused with RBCs to maintain
a hemoglobin level 70 g/L, whereas those in the experimental group were
transfused to maintain a hemoglobin level 120 g/L.
Table 1
Characteristics of Patients, Grafts, and Transplantation Outcomes
Control Group Experimental Group
Patient no. 1 3 4 2 5 6
Diagnosis MDS AML AML Immune deﬁciency AML MDS
Gender Male Female Female Male Female Female
Age, yr 6.1 5.9 15.9 15.1 11.6 15.3
Donor HLA-identical
sibling
HLA-identical
sibling
HLA-identical
sibling
HLA-matched
unrelated
HLA-identical
sibling
HLA-mismatched
related
Conditioning regimen BUCY BUCY BUCY BUCY BUCY BUCY
GVHD prophylaxis MTX-CSA MTX-CSA MTX-CSA MTX-CSA
ATG
MTX-CSA MTX-CSA
ATG
Acute GVHD None None None None Skin, grade I None
Survival status at
day þ100
Alive Alive Alive Alive Alive Alive
MDS indicates myelodysplastic syndrome; AML, acute myeloid leukemia; BUCY, busulfan-cyclophosphamide; MTX, methotrexate; CSA, cyclosporine; ATG,
antithymocyte globulin (thymoglobulin).
Patients in the control group were transfused with RBCs to maintain a hemoglobin level 70 g/L, whereas those in the experimental group were transfused to
maintain a hemoglobin level 120 g/L.
N. Robitaille et al. / Biol Blood Marrow Transplant 19 (2013) 468e473470none was in leukemia relapse at the time of transplantation
[30,31]. In addition, none of them had received a T celle
depleted graft [31,32] or had a Karnovsky score of less than
90% [25]. Transaminase levels were normal for all patients
before transplantation [25,26].
All patients received the same intravenous busulfan-
based chemotherapy in the conditioning regimen [25,33],
and the same target area under the curve (AUC) for busulfan
was used in all of them (AUC0-6h; 1,200 to 1,300 mM  min)
[34]. Furthermore, the AUC0-6h of busulfan was less than
1,500 mM  min in all patients, a threshold reported to be
associated with a higher risk of VOD [35]. All participants
received methotrexate for GVHD prophylaxis with the
same dosing schedule [31,36]. One patient in each arm
received an oral contraceptive (levonorgestrel 150 mg and
ethinylestradiol 30 mg, daily) to suppress menstruation
during posttransplantation thrombopenia [37]. None of
them received amphotericin [26,38]. One patient in the
experimental arm received liposomal amphotericin, which
has not been reported as a risk factor for VOD.
Two patients, one in each arm, were febrile between the
beginning of the conditioning regimen and day þ5. The ratio
of febrile days from the start of the preparative regimen
through day þ 5 was .09 in the experimental arm and .02
in the control arm, both below the .13, .18, and .32 ratios
reported earlier in patients who did not develop VOD,
developed mild-to-moderate VOD, or severe VOD, respec-
tively [26].
The two groups differed in 5 characteristics reported to be
risk factors for VOD: vancomycin treatment; the use of
acyclovir [26]; transfusion with platelet concentrates con-
taining ABO-incompatible plasma, which has been reported
in the autologous transplantation setting [39]; the use of
intravenous immunoglobulin (IVIG) [40-42]; and trans-
plantationwith un unrelated donor, which has been reported
as a risk factor in one study in univariate analysis but not in
multivariate analysis [31]. There were more patients in the
control arm receiving vancomycin (2 versus 1 and acyclovir
(3 vs 2). In the experimental arm, 1 patient received platelet
concentrates containing ABO-incompatible plasma and
another received IVIG. The ﬁrst IVIG transfusionwas given on
day 2 and weekly thereafter at a dose of 500 mg/kg/wk. All 3
patients in the control arm received transplantations from
human leukocyte antigen (HLA)-matched siblings, whereas 1
patient in the experimental arm received a graft from an
unrelated donor and another from an HLA 9/10-matched
relative. The number of patients in each armwas too small toundertake a statistical analysis to correct for these 5 potential
confounders.
Compliance with the protocol was assessed until
day þ100 (control arm) or withdrawal from the transfusion
protocol (experimental arm). RBC transfusions and hemo-
globin levels are detailed in Table 2. The mean hemoglobin
pretransfusion level was 69 g/L in the control group and 106
g/L in the experimental group. After the ﬁrst transfusion, the
mean hemoglobin level was 96 g/L in the control group and
127 g/L in the experimental group. There were no non-
compliant days in the control group versus 3 noncompliant
days in the experimental group (4%). There was no deviation
from the protocol in either armwith regard to RBC or platelet
transfusions above the planned level. The mean length of
storage of the packed RBCs was not signiﬁcantly different
between groups: 26.6 days for the experimental group
versus 24.6 days for the control group.
VOD was diagnosed using the Baltimore criteria, which
deﬁnedVODas an increase inbilirubin greater than34.2mmol/
L before day 21 post-HSCT and two or more of the following
criteria: hepatomegaly, ascites, or weight gain greater than 5%
over baseline [43]. VOD characteristics for each patient are
shown in Table 3. All cases of VOD were remarkably severe:
1 patient required ascites drainage, another hemodialysis, and
a third patient required a hepatic detoxiﬁcation procedure
(molecular adsorbent recycling system).
We reviewed the charts of all previous patients in our
institution who had received an allogeneic transplantation in
conjunction with a myeloablative-conditioning regimen
based on pharmacokinetic-adjusted intravenous busulfan.
The threshold for a transfusion was 70 g/L for all of these
71 consecutive historical control subjects. Patient character-
istics were as follows: median age was 5.6 years, 48% were
male, 63% underwent transplantation for malignant diseases,
and 28% received a graft from an HLA-identical sibling donor.
Table 3
Veno-Occlusive Disease Characteristics, a Hepatic Detoxiﬁcation Procedure
Patient No. 2 5 6
Occurrence, day post-transplant þ19 þ14 þ8
Maximum total bilirubin, mmol/L 312 30 866
Complications Ascites
Hepatic encephalopathy
Coma
Portal vein thrombosis
Ascites
Pleural effusions
Hypoxemia
Ascites
Right pleural effusion
Renal failure
Portal vein thrombosis
Treatments Intensive care
Deﬁbrotide
Antithrombin concentrate
MARS
Supportive care
Drained ascites
Intensive care
Deﬁbrotide
Antithrombin concentrate
Hemodialysis
MARS indicates Molecular Adsorbent Recycling System
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32%, and cyclosporine and steroids in 66% of patients. Five
patients were diagnosedwith VOD according to the Baltimore
criteria, for an incidence of 6%. VOD incidence was not statis-
tically different between the control arm and the historical
cohort. Conversely, the difference between the experimental
arm and the historical control subjects was highly signiﬁcant
(P < .001 with a one-tailed Fischer exact test). Furthermore,
VOD was not as severe in the historical control subjects: only
1 of 5 VOD patients in the historical cohort required ascites
drainage, and only 1 required hemodialysis.
DISCUSSION
The DSMB decision to prematurely close the trial was
motivated by the occurrence of severe VOD in the ﬁrst
3 patients enrolled in the experimental arm. In stark
contrast, none of the 3 patients enrolled in the control arm
experienced VOD (P ¼ .05). Ascites was present in all 3 cases
of VOD, pleural effusion in 2, and portal vein thrombosis in
2. One patient experienced hepatic failure and required
treatment with a molecular adsorbent recycling system,
whereas another required hemodialysis for renal failure. No
major difference was found in known risk factors for VOD
between groups.
An association between a liberal RBC transfusion strategy
and a higher risk of VOD has never been reported. A
randomized clinical trial comparing 2 different RBC trans-
fusion thresholds in critically ill children showed no differ-
ence in survival rate or incidence of adverse events [20].
However, the transfusion threshold trigger in the liberal-
strategy transfusion group was lower (95 g/L) than in the
present study (120 g/L). In a trial involving neonates, the
study did not ﬁnd a higher incidence of adverse events in the
liberal-strategy group, with a transfusion trigger of 85 to
135 g/L [21]. Another trial in preterm neonates found
that major neurologic adverse events were less frequent in
the liberal-strategy transfusion group, with a transfusion
threshold based on respiratory status [44]. A randomized
study in critically ill adult patients reported a trend for lower
survival for the liberal transfusion strategy with a 100 g/L
threshold, but RBC units in this trial were not prestorage
leukoreduced [22]. Three retrospective studies in HSCT
patients reported a beneﬁcial association between high
pretransplantation hemoglobin levels and survival. However,
they also reported that these patients received fewer trans-
fusions [15-17].
Therefore, given the previous data, a higher incidence of
VOD was not expected in this trial, and no speciﬁc stopping
rule was written for such a situation in the standard proce-
dures of the trial. In spite of this, the DSMB ﬁrst suspended
and then stopped the study for safety reasons, taking intoaccount the signiﬁcant difference in the incidence and
severity of the VOD. The difference was found to be statis-
tically signiﬁcant using a Fischer one-tailed exact test. A one-
tailed statistical test was used in this context to test for an
increased risk of an unforeseen adverse event in the exper-
imental arm rather than for a difference between the 2 arms.
The DSMB decision was further supported by the fact that
there was a higher incidence of VOD in the experimental arm
when compared with the historical control subjects inwhich
patientswho had received the same pharmacokinetic-guided
busulfan-based conditioning regimen were given a trans-
fusion based on a 70 g/L threshold (P < .001). Furthermore,
this comparison also revealed that the VOD severity was
greater in the experimental arm than in the historical control
subjects. Although it remains debatable whether deﬁnitive
conclusions can be drawn from this analysis because of the
small number of patients in the experimental arm, the DSMB
concluded that an increased incidence of VOD was highly
probable. In this situation, it was considered unethical to
expose more patients to such a risk.
VOD, also called sinusoidal obstruction syndrome, is a
syndrome characterized by jaundice, painful hepatomegaly,
and ﬂuid retention that may evolve into multiorgan failure.
Several factors have been reported to heighten the risk of VOD
after stem cell transplantation [23-33,35-42].We found some
imbalance for 5 of these factors: the use of vancomycin and
acyclovir (more frequent in the control arm), the use of IVIG,
the use of platelet concentrates containing ABO-incompatible
plasma, and transplantationwith a donor other than an HLA-
matched sibling (more frequent in the experimental arm).
The small number of patients precludes any statistical anal-
ysis to correct for these potential confounders. However,
transplantationwith alternative donors has been found to be
a risk factor in univariate but not multivariate analysis [31].
For the other 4, the imbalance between groups was only with
regard to a difference in 1 patient.
VOD has a complex pathogenesis that involves damage to
sinusoidal endothelial cells and hepatocytes in acinar zone 3
as well as the area surrounding the central veins, with
sinusoidal obstruction being a hallmark of the disease. The
pathogenesis also affects hepatic drug detoxiﬁcation through
the glutathione pathway, cytokine release, generalized
endothelial injury, and ﬁbrogenesis and renders patients in
a hypercoagulable state [23,45]. It has been reported that
storage of RBCs decreases their glutathione synthesis rate
[46]; however, this was due to a decrease in substrate
concentrations in the RBCs and not to the production of
compounds that could interfere with glutathione synthesis
within sinusoidal endothelial cells.
Three other mechanisms can potentially explain the
increased risk of VOD in the experimental group. First,
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in sluggish blood ﬂow that is a recognized risk factor for
thrombosis [47]. Such hyperviscosity can affect the circula-
tion in the hepatic venules by slowing down blood ﬂow,
increasing the risk of VOD. Second, exacerbation of inﬂam-
mation can damage sinusoidal cells. Prestorage leukocyte
reduction reduces the amount of cytokines released by the
white blood cells that remain in RBC units, but it does not
prevent the appearance of many other proinﬂammatory
mediators [48]. For example, echinocytic change in RBCs is
an integral part of the RBC aging process that is accelerated in
stored RBC units. Typically, the tip of the spicules of echi-
nocytes shed microvesicles into supernatant after 2 or 3
weeks of storage (mean length of storage of RBC units was 26
days before use in our patients). These microvesicles contain
lipids that can amplify an inﬂammation [49]. A murine RBC
storage and transfusion model also showed that leukocyte-
reduced, washed, and stored RBCs increase plasma non-
transferrin bound iron, produces tissue iron deposition, and
initiates inﬂammation [50]. Further, we demonstrated in
another study that even leukocyte-reduced RBC units induce
interleukin-6 release by white blood cells [51]. The trans-
fusion of RBC units that contain cytokines and/or other pro-
inﬂammatory mediators released by white blood cells may
thusbe implicated in theoccurrenceofVOD thatweobserved.
Third, a great deal of data suggest that the transfusion of RBC
unitsmaygenerate a procoagulant state, increasing the risk of
thrombosis. For example, microvesicles shed by RBCs bind
annexin V, resulting in a procoagulant state, which facilitates
generation of thrombin (known as a transfusion-induced
facilitation of thrombin, or TRIFT effect). This might increase
the risk of thrombosis when RBC units stored more than
3weeks are used [49]. Moreover, in stored RBC units, atypical
translocation of phosphatidyl-serine to RBC membranes is
observed over time. This is associated with increased
adherence of RBCs and with more aggregation. In addition,
phosphatidyl-serine on the surface of RBCs has been reported
to cause platelet activation and aggregation, which can be
prothrombotic [52]. All these mechanisms may explain why
weobserveda severeVOD inall 3patients in theexperimental
group assigned to receive an RBC transfusion with a high
hemoglobin thresholdof120g/L andnot in the3patientswith
a low threshold of 70 g/L.
In conclusion, although this trial was designed to explore
another outcome, it showed that a liberal hemoglobin
threshold of 120 g/L for RBC transfusion may harbor a risk for
VOD after HSCT. Further studies are needed to clarify the
magnitude of that risk and to unravel its cause [19]. While
awaiting the results of these studies, the risk-to-beneﬁt
ratio of using a high hemoglobin level transfusion trigger
should be carefullyweighed. Therefore, following the current
conservative approach of applying a low hemoglobin
threshold level of 70 g/L as the trigger for RBC transfusion
should be considered as the standard of care for patients
undergoing HSCT.
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